Home / Pipeline / Meningococcal polysaccharide diphtheria toxoid conjugate + Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate Products Meningococcal polysaccharide diphtheria toxoid conjugate + Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
Meningococcal polysaccharide diphtheria toxoid conjugate + Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate Approved Completed ⚡ Active Interest: 43/100
Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Jul 1, 2012 → Sep 1, 2015
About Meningococcal polysaccharide diphtheria toxoid conjugate + Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate Meningococcal polysaccharide diphtheria toxoid conjugate + Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate is a approved stage product being developed by Sanofi for Meningitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01659996. Target conditions include Meningitis, Meningococcal Infection, Diphtheria.
What happened to similar drugs? 2 of 20 similar drugs in Meningitis were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT01659996 Approved Completed Jul 1, 2012 Sep 1, 2015 Meningitis
Product Company Stage Hype Score RotaTeq® + NeisVac-C® Merck Phase 3 Daptomycin Merck Pre-clinical Meningococcal ACWY conjugate vaccine Novartis Phase 3 Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine Novartis Approved Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP Novartis Phase 3 Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and Menveo Novartis Phase 3 Meningococcal ACWY conjugate vaccine Novartis Phase 3 MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + Varicella Novartis Phase 2 Hib-CRM197 + Hib-TT Novartis Phase 3 Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate Vaccine Novartis Phase 3 MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvanted Novartis Phase 2 meningococcal B vaccine & meningococcal ACYW conjugate vaccine Novartis Phase 2 Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine Novartis Phase 2 4CMenB Novartis Approved Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine Novartis Phase 3 Meningococcal (group B) multicomponent recombinant adsorbed vaccine Novartis Phase 3 MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose) Novartis Phase 3 MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A Virus Novartis Phase 3 Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years) Novartis Phase 3 Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyretic Novartis Phase 2